Feedback
Settings

Settings

Goto Application

1,510 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

FP:(EBOLA)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

6 / 151
51.118252937Application of antagonist of CXCR4 receptor in resisting Ebola virus infection
CN - 28.06.2024
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No 202410405576.X Applicant SUN YAT-SEN UNIVERSITY Inventor QIAN JUN
The invention discloses an application of an antagonist of a CXCR4 receptor in resisting Ebola virus infection, the CXCR4 and envelope glycoprotein GP of the Ebola virus have specific interaction, the CXCR4 is a key cell surface receptor for mediating adsorption and entering of the Ebola virus into a host cell, and the CXCR4 receptor antagonist, a CXCR4 antibody and a reagent for inhibiting expression of a CXCR4 gene and/or CXCR4 protein are used for inhibiting the Ebola virus infection. The Ebola virus can be obviously inhibited from being adsorbed and entering target cells, so that the effect of resisting Ebola virus infection is achieved. The invention provides a new defense means for resisting the fulminating infectious diseases.
52.WO/2024/138155EBOLAVIRUS (SUDAN AND ZAIRE) ANTIBODIES FROM NON-HUMAN PRIMATES AND HUMAN VACCINEES
WO - 27.06.2024
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
 Appl.No PCT/US2023/085745 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor SULLIVAN, Nancy J.
Monoclonal antibodies and bispecific monoclonal antibodies that bind Sudan virus (SUDV) and/or Ebola virus (EBOV) glycoprotein (GP) with nanomolar affinity are described. The monoclonal antibodies were developed by single-cell sorting of B cells obtained from non-human primate and human subjects previously immunized with Ebola (Zaire) virus (EBOV) and Sudan virus (SUDV) glycoprotein. Use of the monoclonal antibodies and bispecific antibodies for treating, inhibiting, and detecting infection by SUDV and EBOV is also described.
53.WO/2024/138151EBOLAVIRUS (SUDAN AND ZAIRE) ANTIBODIES FROM NON-HUMAN PRIMATES AND HUMAN VACCINEES
WO - 27.06.2024
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
 Appl.No PCT/US2023/085739 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor SULLIVAN, Nancy J.
Monoclonal antibodies that bind Sudan virus (SUDV) and/or Ebola virus (EBOV) glycoprotein (GP) with nanomolar affinity are described. The monoclonal antibodies were developed by single-cell sorting of B cells obtained from non-human primate and human subjects previously immunized with Ebola (Zaire) virus (EBOV) and Sudan virus (SUDV) glycoprotein. Use of the monoclonal antibodies for treating, inhibiting, and detecting infection by SUDV and EBOV is also described.
54.103355DƯỢC PHẨM CHỨA HỢP CHẤT ĐỂ ĐIỀU TRỊ HOẶC NGĂN NGỪA LÂY NHIỄM VIRUT
VN - 25.06.2024
Int.Class A61K 31/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
 Appl.No 1202307505 Applicant Emory University Inventor George R. PAINTER
Sáng chế đề cập đến dược phẩm chứa hợp chất có công thức XXVIII,

để điều trị hoặc phòng bệnh nhiễm virut. Các bệnh nhiễm virut này có thể bao gồm tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picomaviridae, bệnh viêm não ngựa miền Đông, miền Tây và Venezuela (EEE, WEE và VEE, tương ứng), sốt Chikungunya (CHIK), Ebola, bệnh cúm, RSV, và bệnh nhiễm virut Zika.
55.WO/2024/130061IMMUNOGENIC EBOLAVIRUS FUSION PROTEINS AND RELATED METHODS
WO - 20.06.2024
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2023/084184 Applicant CZ BIOHUB SF, LLC Inventor XU, Duo
Provided are fusion proteins including an artificially modified amino acid sequence of an ebolavirus glycoprotein (GP) joined to an amino acid sequence of a ferritin subunit polypeptide. An artificially modified amino acid sequence of an ebolavirus GP includes artificially installed glycosylation sites. Nanoparticles including fusion proteins, with surface-exposed trimers of the ebolavirus GP, are also provided. Also provided are nucleic acids and vectors encoding the fusion proteins, cells containing such nucleic acid and vectors, immunogenic compositions including the fusion proteins, the nanoparticles, or the vectors, as well as corresponding methods and kits.
56.20240189335N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US - 13.06.2024
Int.Class C07H 19/067
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
067with ribosyl as the saccharide radical
 Appl.No 18390347 Applicant EMORY UNIVERSITY Inventor George R. Painter

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.

57.WO/2024/118795PEPTIDES AND PEPTIDE MICROARRAYS FOR DETECTION AND DIFFERENTIATION OF ANTIBODY RESPONSES TO EBOLA VIRUS
WO - 06.06.2024
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/US2023/081625 Applicant THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Inventor MISHRA, Nischay
Peptides, platforms and methods for detecting antibody responses to filovirus infections, detecting antibody responses to EBOV infection, and detecting antibody responses to vaccination by EBOV vesicular stomatitis virus-based vaccine.
58.20240181045Dendritic Cell-Targeting Universal Vaccine for Influenza Infection
US - 06.06.2024
Int.Class A61K 39/295
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
 Appl.No 17768624 Applicant University of Manitoba Inventor Xiao-Jian Yao

We have recently developed a novel DC-targeting vaccine platform using Ebola glycoprotein (EboGP) DC-targeting domain-based fusion protein technology. Here, we will use this technology to generate universal vaccines against Influenza A by fusing a DC-targeting/activation domain (EboGPAM), derived from EboGP to I) a tetrameric conserved extracellular domain of M2 (M2e) of Influenza A strains from human, birds, and swine; 2) the conserved stalk regions (HAcs) of HA and an M2 polypeptide from H5N1 strain; and 3) the HA head regions polypeptides (HAH5-1-3) derived from H5N1, H1 N1 and H3N2 strains.

59.202401809484'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO
US - 06.06.2024
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
 Appl.No 18359435 Applicant EMORY UNIVERSITY Inventor George R. PAINTER

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

60.311888EBOLA PSEUDOTYPED VECTORS AND METHODS OF USE THEREOF
IL - 01.06.2024
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No 311888 Applicant INTERIUS BIOTHERAPEUTICS, INC. Inventor
# -